The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
pu luo pa tong zhuan fu ji yu fang fang chan
Pages: 230-231
Year: Issue:  4
Journal: World Clinical Drugs

Keyword:  普罗帕酮窦性心律复律慢性房颤心衰症状电转复房颤病人心功能心源性休克安慰剂对照;
Abstract: 本文旨在经多中心、随机、双盲、安慰剂对照前瞻性临床试验,以检测静注或口服普罗帕酮(propafenone)快速终止房颤及维持窦性心律的疗效及安全性。1方法年龄在18岁以上,新近首次发作或复发房颤(<2周)及慢性房颤(>2周)的病人进入研究。但心功能Ⅱ级、有心衰症状、新近心肌梗死或心脏手术、心源性休克或高血压等病人不包括在内。符合要求的病人以双盲法按3:1随机分为普罗帕酮组或安慰剂组。试验包括两期:急性转律期与药物或直流电转复为窦性心律后6个月预防房颤的长期维持期。所有病人都住院监护,给予抗凝剂预防血栓事件。将本品2mg/Kg加入5%葡萄糖液中30分钟内静脉注射,或静注相应的安慰剂,静注后2小时
Related Articles
No related articles found